surmount-1 trial tirzepatide non-diabetic weight loss SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, Tirzepatide after intensive lifestyle intervention

AIM2 regulates autophagy to mitigate oxidative stress in aged mice with acute liver injury

The commonly used chemotherapeutic drug sorafenib is resistant to treatment in patients with advanced HCC

Tirzepatide is unique because it functions as a dual GLP-1/GIP receptor agonist

Signaling molecules of the NF-B pathway shuttle constitutively between cytoplasm and nucleus

When to stop tracking Once you can consistently hit 100 to 130 grams of protein without logging, you have internalized the framework

The 0.01 mg/kg dose that showed consistent effects in rats translates to approximately 0.0016 to 0.004 mg/kg in humans, which works out to roughly 0.112 to 0.28 mg for a 154-pound person